Q4 2023 Aurobindo Pharma Ltd Earnings Call Transcript
Good morning, and welcome to Aurobindo Pharma Quarter 4 FY '23 Earnings Call. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to the management for opening remarks. Thank you, and over to you.
Thank you, [Ambit]. Good morning, and a warm welcome to our fourth quarter FY '23 earnings call. I'm Deepti Thakur from the Investor Relations team. We hope you have received the quarter 4 FY '23 financials and the press release that was sent out on Saturday. These are also available on our website.
I would like to introduce my senior management team today on the call with us, represented by Dr. Satakarni Makkapati, CEO of Aurobindo Biosimilars, Vaccines and Peptide businesses; Mr. Yugandhar Puvvala, CEO of Eugia Pharma Specialities Limited; Mr. Sanjeev Dani, COO and Head Formulations, Aurobindo Pharma Limited; Mr. Swami Iyer, CEO, Aurobindo Pharma USA; and Mr. S. Subramanian, CFO.
We will begin the call with summary highlights from the management followed by an interactive Q&A
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |